Is Halozyme Therapeutics a Better Buy Than United Therapeutics?
United Therapeutics surged 11% during the past Week. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Halozyme Therapeutics gives you more. Halozyme Therapeutics (HALO) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs United Therapeutics (UTHR) stock, suggesting you may be better off investing in HALO
- HALO’s quarterly revenue growth was 51.6%, vs. UTHR’s 7.4%.
- In addition, its Last 12 Months revenue growth came in at 37.6%, ahead of UTHR’s 10.6%.
- HALO leads on profitability over both periods – LTM margin of 57.5% and 3-year average of 50.8%.
These differences become even clearer when you look at the financials side by side. The table highlights how UTHR’s fundamentals stack up against those of HALO on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| UTHR | HALO | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 15.6 | 9.7 | HALO |
| Revenue Growth | |||
| Last Quarter | 7.4% | 51.6% | HALO |
| Last 12 Months | 10.6% | 37.6% | HALO |
| Last 3 Year Average | 18.1% | 28.5% | HALO |
| Operating Margins | |||
| Last 12 Months | 47.6% | 57.5% | HALO |
| Last 3 Year Average | 49.6% | 50.8% | HALO |
| Momentum | |||
| Last 3 Year Return | 138.1% | 59.7% | UTHR |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: UTHR Revenue Comparison | HALO Revenue Comparison
See more margin details: UTHR Operating Income Comparison | HALO Operating Income Comparison
- Is IVV’s Growth Engine Worth The Price Of Admission?
- Does Constellation Energy Stock’s Surge Broaden Your Portfolio Or Just Amplify It?
- Google Has The Best Problem Money Can’t Quite Buy
- How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story
- Who Really Powered VGT’s Climb This Year?
- Is The AI Super-Cycle Real Enough To Bet On Micron Stock?
See detailed fundamentals on Buy or Sell HALO Stock and Buy or Sell UTHR Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| UTHR Return | 42% | 29% | -21% | 60% | 38% | 10% | 253% | <=== | |
| HALO Return | -6% | 42% | -35% | 29% | 41% | 1% | 59% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% | ||
| Monthly Win Rates [3] | |||||||||
| UTHR Win Rate | 67% | 42% | 42% | 58% | 50% | 67% | 54% | ||
| HALO Win Rate | 42% | 58% | 33% | 50% | 58% | 33% | 46% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | 60% | <=== | |
| Max Drawdowns [4] | |||||||||
| UTHR Max Drawdown | 0% | -23% | -26% | -4% | -22% | -5% | -13% | ||
| HALO Max Drawdown | -25% | -20% | -47% | -9% | -0% | 0% | -17% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | -8% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 3/11/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read HALO Dip Buyer Analyses and UTHR Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about UTHR or HALO? Consider portfolio approach.
Portfolios Over Individual Stock Picks
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.